MiR-155 inhibits TP53INP1 expression leading to enhanced glycolysis of psoriatic mesenchymal stem cells

Liu, Yanmin; Zhao, Xincheng; Li, Juan; Zhou, Ling; Chang, Wenjuan; Hou, Ruixia; Yin, Guohua; Li, Xinhua; Zhang, Kaiming

doi:10.1016/j.jdermsci.2022.02.001

Cited by 8 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…345 MiR-155 is a central regulatory miRNA that is simultaneously involved in the regulation of multiple genes critical for functional epidermal development. 352 MiR-155 has been found upregulated in psoriatic skin lesions, LPS-induced keratinocytes, and monocytes [353][354][355][356][357] and to further regulate psoriatic processes, including the proliferation of psoriatic mesenchymal (PM) stem cells, the release of cytokines or chemokines of psoriatic keratinocytes, and Th17 inflammatory responses. With regard to the mechanism, miR-155 regulates the production of IL-6 and CXCL8 in keratinocytes through the GATA3/ IL-37 regulatory axis.…”

Section: Histone Modificationsmentioning

confidence: 99%

Signaling pathways and targeted therapies for psoriasis

Guo,

Zhang,

Lin

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Psoriasis is a common, chronic, and inflammatory skin disease with a high burden on individuals, health systems, and society worldwide. With the immunological pathologies and pathogenesis of psoriasis becoming gradually revealed, the therapeutic approaches for this disease have gained revolutionary progress. Nevertheless, the mechanisms of less common forms of psoriasis remain elusive. Furthermore, severe adverse effects and the recurrence of disease upon treatment cessation should be noted and addressed during the treatment, which, however, has been rarely explored with the integration of preliminary findings. Therefore, it is crucial to have a comprehensive understanding of the mechanisms behind psoriasis pathogenesis, which might offer new insights for research and lead to more substantive progress in therapeutic approaches and expand clinical options for psoriasis treatment. In this review, we looked to briefly introduce the epidemiology, clinical subtypes, pathophysiology, and comorbidities of psoriasis and systematically discuss the signaling pathways involving extracellular cytokines and intracellular transmission, as well as the cross-talk between them. In the discussion, we also paid more attention to the potential metabolic and epigenetic mechanisms of psoriasis and the molecular mechanistic cascades related to its comorbidities. This review also outlined current treatment for psoriasis, especially targeted therapies and novel therapeutic strategies, as well as the potential mechanism of disease recurrence.

show abstract

Section: Histone Modificationsmentioning

confidence: 99%

Signaling pathways and targeted therapies for psoriasis

Guo,

Zhang,

Lin

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…In particular, the Circular RNA (circRNA) gene chr2:206992521|206994966 is mostly expressed by PsO-MSCs and affects the activity of T lymphocytes in local lesions by influencing their pro-inflammatory cytokine secretion (IL-6, IL-11, and hepatocyte growth factor) [ 36 ]. Another miRNA expressed by PsO-MSCs is MicroRNA-155 (MiR-155), which is involved in the pathogenesis of both inflammation and glucose metabolism in psoriasis and regulates the expression levels of various cytokines and enhances the glycolysis in psoriasis [ 37 ].…”

Section: Resultsmentioning

confidence: 99%

Mesenchymal Stem Cells and Psoriasis: Systematic Review

Diotallevi

Vincenzo

Martina

et al. 2022

IJMS

View full text Add to dashboard Cite

Mesenchymal Stem Cells (MSCs) are multipotent non-hematopoietic stromal cells found in different body tissues such as bone marrow, adipose tissue, periosteum, Wharton’s jelly, umbilical cord, blood, placenta, amniotic fluid, and skin. The biological behavior of MSCs depends mainly on their interaction with the microenvironment in which they are found, whose quality deeply influences the regenerative and immunomodulatory properties of these cells. Several studies confirm the interaction between MSCs and inflammatory microenvironment in the pathogenesis of psoriasis, designating MSCs as an important factor driving psoriasis development. This review aims to describe the most recent evidence on how the inflammatory microenvironment that characterizes psoriasis influences the homeostasis of MSCs and how they can be used to treat the disease.

show abstract

“…Recently, Liu et al [59] confirmed the potential role of miR-155 in psoriasis pathogenesis through its upregulation in psoriasis, promoting proliferation, migration, inflammatory response and metabolite levels of MSCs, while inhibiting apoptosis [59]. In comparison with MSCs obtained from healthy individuals, the authors demonstrated that the glycolysis levels were increased in MSCs obtained from psoriasis patients and this increase was related to miR-155 expression through the negative regulation of the TP53INP1/p53 signaling pathway.…”

Section: Inflammatory Skin Diseases 221 Psoriasismentioning

confidence: 96%

miRNAs, Mesenchymal Stromal Cells and Major Neoplastic and Inflammatory Skin Diseases: A Page Being Written: A Systematic Review

Vincenzo

Diotallevi

Piccirillo

et al. 2023

IJMS

View full text Add to dashboard Cite

Micro RNAs (miRNAs) are a type of non-coding RNA (ncRNA) and typically interact with specific target mRNAs through complementary base pairing, affecting their translation and/or stability. MiRNAs regulate nearly all cellular functions, including the cell fate of mesenchymal stromal cells (MSCs). It is now accepted that various pathologies arise at the stem level, and, in this scenario, the role played by miRNAs in the fate of MSCs becomes of primary concern. Here we have considered the existing literature in the field of miRNAs, MSCs and skin diseases, classified as inflammatory (such as psoriasis and atopic dermatitis-AD) and neoplastic (melanoma and non-melanoma-skin-cancer including squamous cell and basal cell carcinoma) diseases. In this scoping review article, the evidence recovered indicates that this topic has attracted attention, but it is still a matter of opinion. A protocol for this review was registered in PROSPERO with the registration number “CRD42023420245”. According to the different skin disorders and to the specific cellular mechanisms considered (cancer stem cells, extracellular vesicles, inflammation), miRNAs may play a pro- or anti-inflammatory, as well as a tumor suppressive, or supporting, role, indicating a complex regulation of their function. It is evident that the mode of action of miRNAs is more than a switch on–off, and all the observed effects of their dysregulated expression must be checked in a detailed analysis of the targeted proteins. The involvement of miRNAs has been studied mainly for squamous cell carcinoma and melanoma, and much less in psoriasis and AD; different mechanisms have been considered, such as miRNAs included in extracellular vesicles derived both from MSCs or tumor cells, miRNAs involved in cancer stem cells formation, up to miRNAs as candidates to be new therapeutic tools.

show abstract

MiR-155 inhibits TP53INP1 expression leading to enhanced glycolysis of psoriatic mesenchymal stem cells

Cited by 8 publications

References 32 publications

Signaling pathways and targeted therapies for psoriasis

Signaling pathways and targeted therapies for psoriasis

Mesenchymal Stem Cells and Psoriasis: Systematic Review

miRNAs, Mesenchymal Stromal Cells and Major Neoplastic and Inflammatory Skin Diseases: A Page Being Written: A Systematic Review

Contact Info

Product

Resources

About